Biomarin Prism 301-A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety and Tolerability of an Induction, Titration and Maintenance Dose Regimen of BMN 165 Self Administered by Adults with Phenylketonuria Not Previously Treated with